Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022
Chinook Therapeutics (Nasdaq: KDNY) announced participation in the William Blair Biotech Focus Conference 2022, featuring a fireside chat available on-demand starting July 11 at 9:00 am EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics (Nasdaq: KDNY) announced participation in the William Blair Biotech Focus Conference 2022, featuring a fireside chat available on-demand starting July 11 at 9:00 am EDT. The management will also engage in 1x1 meetings on July 12 in New York, NY. Chinook is focused on developing precision medicines for kidney diseases, with its lead program, atrasentan, in phase 3 for IgA nephropathy. Further details and archived presentations can be accessed via the company's Investors section.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was +1.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a fireside chat and 1x1 meetings at the William Blair Biotech Focus Conference 2022. The fireside chat will be available on-demand beginning Monday, July 11th at 9:00 am EDT and Chinook management will participate in 1x1 meetings in New York, NY on Tuesday, July 12th.
To access the webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.